6615.TWO · SOFIVA
Taiwan · RS rating 40 · As of 2026-10-08
| Price | 33.35 TWD |
|---|---|
| 1-day change | +0.1% |
| RS rating (overall / 1M / 3M / 12M) | 40 / 29 / 31 / 62 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 25 / 29 |
| Industry group (rank) | Medical-Biomed/Biotech (53) |
| EPS growth Q/Q | -62.7% |
| Sales growth Q/Q | +4.3% |
| Distance from 52-week high | +11.5% |
| Market cap (USD) | $22.8M |